IP Library › Patent Application 11045024
Patent Application
App. No. 11/045,024

Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/045,024
Abstract

This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare human immunodeficiency virus (HIV) epitopes, and to develop epitope-based vaccines directed towards HIV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HIV infection.

Claims (72)

1 - 40 . (canceled)

41 . An isolated peptide less than 15 amino acids in length comprising a sequence selected from the group consisting of:

VLAEAMSQV

(SEQ ID NO:14422)

ILKEPVHGV

(SEQ ID NO:14457)

KVYLAWVPAHK

(SEQ ID NO:14439)

KIQNFRVYYR

(SEQ ID NO:14440)

VTVYYGVPVWK

(SEQ ID NO:14445)

and

QMAVFIHNFK.

(SEQ ID NO:14438)

42 . A composition comprising the peptide of claim 41 and one or more members selected from the group consisting of:

(a) an immunogenic peptide;

(b) a spacer molecule;

(c) a carrier;

(d) a lipid;

(e) a liposome; and

(f) an antigen presenting cell.

43 . A composition according to claim 42 , wherein said immunogenic peptide comprises a T helper cell epitope.

44 . A composition according to claim 43 , wherein said T helper cell epitope is a universal T helper cell epitope.

45 . A composition according to claim 42 , wherein said immunogenic peptide comprises a CTL epitope.

46 . A composition according to claim 45 , wherein said CTL epitope comprises a sequence selected from the group consisting of:

VLAEAMSQV

(SEQ ID NO:14422)

ILKEPVHGV

(SEQ ID NO:14457)

KVYLAWVPAHK

(SEQ ID NO:14439)

KIQNFRVYYR

(SEQ ID NO:14440)

VTVYYGVPVWK

(SEQ ID NO:14445)

and

QMAVFIHNFK.

(SEQ ID NO:14438)

47 . A composition according to claim 42 , wherein said antigen presenting cell is a dendritic cell.

48 . An isolated nucleic acid minigene construct which encodes a peptide epitope, wherein said peptide epitope comprises a sequence selected from the group consisting of:

VLAEAMSQV

(SEQ ID NO:14422)

ILKEPVHGV

(SEQ ID NO:14457)

KVYLAWVPAHK

(SEQ ID NO:14439)

KIQNFRVYYR

(SEQ ID NO:14440)

VTVYYGVPVWK

(SEQ ID NO:14445)

and

QMAVFIHNFK.

(SEQ ID NO:14438)

49 . An isolated nucleic acid minigene construct according to claim 48 , wherein said construct also encodes a second peptide epitope.

50 . An isolated nucleic acid minigene construct according to claim 49 , wherein said second peptide epitope comprises a T helper cell epitope.

51 . An isolated nucleic acid minigene construct according to claim 50 , wherein said T helper cell epitope is a universal T helper cell epitope.

52 . An isolated nucleic acid minigene construct according to claim 49 , wherein said second peptide epitope comprises a CTL epitope.

53 . An isolated nucleic acid minigene construct according to claim 52 , wherein said CTL epitope comprises a sequence selected from the group consisting of:

VLAEAMSQV

(SEQ ID NO:14422)

ILKEPVHGV

(SEQ ID NO:14457)

KVYLAWVPAHK

(SEQ ID NO:14439)

KIQNFRVYYR

(SEQ ID NO:14440)

VTVYYGVPVWK

(SEQ ID NO:14445)

and

QMAVFIHNFK.

(SEQ ID NO:14438)

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2006
From: IDM PHARMA, INC.
To: PHARMEXA INC.
Reel/Frame 017115/0860 →
MERGER Recorded Feb 3, 2006
From: EPIMMUNE INC.
To: IDM PHARMA, INC.
Reel/Frame 017115/0312 →